Asthma is a chronic condition characterized by shortness of breath, wheezing, and coughing due to the narrowing of the bronchi. Asthma that has symptoms concerning the bronchi is commonly referred to as bronchial asthma. Bronchodilators are designed to help this narrowing of the bronchi in the event of an asthma attack. There are also bronchodilators made to prevent the narrowing of the bronchi.
Asthma usually develops in children and is sometimes outgrown when they reach a certain age. Continuous exposure to triggers when they are older risks the recurrence of asthma. Non-asthmatics may also develop asthma when left on similar toxic environments due to infection.
A non-asthmatic naturally does not carry inhalers with them. They dont really need it. But in the event of a mild or acute asthma attack, especially one that happens for the first time, they still need bronchodilators. Bronchodilators commonly come in the form of albuterol, or salbutamol. But another inhaled bronchodilator was designed to relieve acute or new asthma symptoms.
Ipratropium is a tea extract developed into a drug for treatment of chronic obstructive lung diseases. It is a anticholinergic and is pharmacological structure is similar to that of caffeine. Ipratropium is primarily a treatment drug for COPD. But it has been applied in asthma. It has been considered as a short-acting bronchodilator even though it takes about an hour for full effectiveness. Because of this, it is almost always combined with albuterol or salbutamol.
Anticholinergics generally have side-effects similar to those experienced in recreational drug use. The difference is it has no addiction factor " most probably due to the lack of euphoria caused by them. The strongest point of ipratropium bromide is that it has no side-effects related to the heart " a common thing among bronchodilators. With this said, it can be safely taken by those who have heart complications. This is also an alternative for those who experience asthma symptoms for the first time.
No related posts.
Comments on this entry are closed.